COA
- Product Details
- Performance Data
- Reviews & Citations
ID | Components | Size |
EP115-C01 | Pre-coated Human ACE2 Microplate | 1 plate |
EP115-C02 | SARS-CoV-2 Inhibitor | 20 μg |
EP115-C03 | HRP-SARS-CoV-2 Spike RBD(B.1.1.529) | 15 μg |
EP115-C04 | 10xWashing Buffer | 50 mL |
EP115-C05 | Dilution Buffer | 50 mL |
EP115-C06 | Substrate Solution | 12 mL |
EP115-C07 | Stop Solution | 7 mL |
As of Nov 29th, confirmed cases of a new variant of concern (VOC) B.1.1.529 have been reported in South Africa, Botswana and more than 12 other countries. Thanks to the rapid sequencing efforts of South African scientists, the whole world is now alerted about this potentially devastating lineage, which was assigned the name Omicron by WHO.Omicron is a highly divergent variant with a high number of mutations (26-35) in the spike. Identification of some familiar mutations that also appeared on other VOCs gives rises to concerns of its immune escape potential and higher transmissibility,it is necessary to develop SARS-CoV-2 inhibitors, such as vaccines，therapeutic antibodies and small molecule compounds against SARS-CoV-2(B.1.1.529). The SARS-CoV-2 (B.1.1.529) Inhibitor Screening Kit (Spike RBD) is helpful to develop the to test SARS-CoV-2 inhibitors.
This kit is developed for screening inhibitors of SARS-CoV-2 (B.1.1.529).
It is for research use only.
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.